New trial
Phase II Hypofractionated EBRT, fine-tuning targeted ionizing radiation for nodal control in breast cancer.
- Trial ID
- NCT07076485 on ClinicalTrials.gov
- Cancer type
- Breast Cancer
- Stage of research
- Exploratory
- Published in
- New in Oncology - Aug 15, 2025 (DOUBLE ISSUE)
This Phase II trial at M.D. Anderson evaluates shortened adjuvant regional nodal irradiation schedules using hypofractionated external beam radiation therapy (EBRT) via different dose regimens, including simultaneous integrated boost options, in patients with invasive breast cancer following lumpectomy or mastectomy. The multi-cohort study stratifies high-risk and low-risk groups to identify optimal radiation schedules.
More in breast cancer
-
Trial result · Oct 22, 2026 · NCT02364557
NRG-BR002: Metastasis-directed ablation (SBRT/surgery) fails to extend PFS in oligometastatic breast cancer on 1L systemic therapy -
Trial result · Oct 22, 2026 · NCT05963984
Samuraciclib + fulvestrant shows higher clinical benefit and numerically longer PFS after CDK4/6 inhibition in randomized Phase 2 breast cancer trial -
Trial result · Oct 15, 2026 · NCT05306340
Giredestrant (oral SERD) + everolimus improves PFS after CDK4/6 inhibition, with the strongest benefit in ESR1-mutated breast cancer -
Trial result · Oct 15, 2026 · NCT02264678
Ceralasertib (ATR inhibitor) + Olaparib (PARP inhibitor) hits 37.8% ORR in PARPi‑naïve BRCA‑mut HER2‑neg breast cancer -
New trial · Oct 15, 2026 · NCT07844759
Pilot study tests single-fraction stereotactic radiation plus endocrine therapy without lumpectomy in early breast cancer